Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Sos ML, Koker M, Weir BA, Heynck S, et al. Cancer Res 2025;85:1003.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sos ML, Koker M, Weir BA, Heynck S, et al. Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Cancer Res 2025;85:1003.
PMID: 40025966